Abstract
Pharmacological interventions that increase myofiber size counter the functional decline of dystrophic muscles1,2. We show that deacetylase inhibitors increase the size of myofibers in dystrophin-deficient (MDX) and α-sarcoglycan (α-SG)–deficient mice by inducing the expression of the myostatin antagonist follistatin3 in satellite cells. Deacetylase inhibitor treatment conferred on dystrophic muscles resistance to contraction-coupled degeneration and alleviated both morphological and functional consequences of the primary genetic defect. These results provide a rationale for using deacetylase inhibitors in the pharmacological therapy of muscular dystrophies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Engvall, E. & Wewer, U.M. FASEB J. 17, 1579–1584 (2003).
Zammit, P.S. & Partridge, T.A. Nat. Med. 8, 1355–1356 (2002).
Lee, S.J. Annu. Rev. Cell Dev. Biol. 20, 61–86 (2004).
Bogdanovich, S. et al. Nature 420, 418–421 (2002).
Wagner, K.R., McPherron, A.C., Winik, N. & Lee, S.J. Ann. Neurol. 52, 832–836 (2002).
Barton, E.R., Morris, L., Musaro, A., Rosenthal, N. & Sweeney, H.L. J. Cell Biol. 157, 137–148 (2002).
Iezzi, S., Cossu, G., Nervi, C., Sartorelli, V. & Puri, P.L. Proc. Natl. Acad. Sci. USA 99, 7757–7762 (2002).
Iezzi, S. et al. Dev. Cell 6, 673–684 (2004).
Emery, A.E. Lancet 359, 687–695 (2002).
Rafael, J.A., Tinsley, J.M., Potter, A.C., Deconinck, A.E. & Davies, K.E. Nat. Genet. 19, 79–82 (1998).
Duclos, F. et al. J. Cell Biol. 142, 1461–1471 (1998).
Parsons, S.A., Millay, D.P., Sargent, M.A., McNally, E.M. & Molkentin, J.D. Am. J. Pathol. 168, 1975–1985 (2006).
Puri, P.L. et al. Mol. Cell 8, 885–897 (2001).
Canettieri, G. et al. Nat. Struct. Biol. 10, 175–181 (2003).
Saito, A. et al. Proc. Natl. Acad. Sci. USA 96, 4592–4597 (1999).
Acknowledgements
We thank K.P. Campbell (Howard Hughes Medical Institute, University of Iowa) for providing α-SG–deficient mice, G. Cossu. and E. Engvall for critically reading the manuscript, and Alberto Bordonaro for the art work on figures. P.L.P is an assistant Telethon scientist at the Dulbecco Telethon Institute. This work was supported by a Telethon Special Grant to P.L.P. and R.B.; Muscular Dystrophy Association, Parent Project Organization and Compagnia San Paolo di Torino grants to P.L.P.; a European Union Grant and a Telethon Grant to M.C.C.; an Associazione Italiana Ricerca sul Cancro Regional Grant to C.G.; Cariplo Foundation and Italian Space Agency grants to R.B.; and grants from the Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the US National Institutes of Health to M.D.P and V.S.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
P.G. and C.S. are employees of the Istituto di Ricerca di Biologia Molecolare—Merck Research Laboratories.
Supplementary information
Supplementary Fig. 1
Levels of histone acetylation in peripheral tissues of untreated and TSA, VPA or PHB-treated MDX mice. (PDF 199 kb)
Supplementary Fig. 2
Myogenic potential of satellite cells isolated from muscles of untreated and TSA, VPA or PHB-treated MDX mice. (PDF 1819 kb)
Supplementary Fig. 3
Improvement in muscle strength and function and levels of utrophin and dystrophin in untreated and TSA-treated MDX mice. (PDF 75 kb)
Supplementary Fig. 4
Distribution of fiber CSA and frequency histograms of single-fiber CSA in muscles from untreated and TSA-treated MDX mice. (PDF 78 kb)
Supplementary Fig. 5
Desmin-positive cells in muscle from untreated versus TSA-treated MDX mice. (PDF 55 kb)
Supplementary Fig. 6
Morphological and histological changes in muscles from untreated and TSA-treated MDX mice. (PDF 195 kb)
Supplementary Fig. 7
Myogenic potential of satellite cells isolated from muscles of α-SG–deficient mice untreated or TSA-treated; distribution of CSA and Azan Mallory staining of muscles from untreated and TSA-treated α-SG–deficient mice. (PDF 2836 kb)
Supplementary Fig. 8
Morphological and functional effects of MS 27-275 on MDX mice. (PDF 1144 kb)
Rights and permissions
About this article
Cite this article
Minetti, G., Colussi, C., Adami, R. et al. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat Med 12, 1147–1150 (2006). https://doi.org/10.1038/nm1479
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1479
This article is cited by
-
Pharmacological inhibition of HDAC6 improves muscle phenotypes in dystrophin-deficient mice by downregulating TGF-β via Smad3 acetylation
Nature Communications (2022)
-
Origins, potency, and heterogeneity of skeletal muscle fibro-adipogenic progenitors—time for new definitions
Skeletal Muscle (2021)
-
Epigenetic modifications in muscle regeneration and progression of Duchenne muscular dystrophy
Clinical Epigenetics (2021)
-
The pan HDAC inhibitor Givinostat improves muscle function and histological parameters in two Duchenne muscular dystrophy murine models expressing different haplotypes of the LTBP4 gene
Skeletal Muscle (2021)
-
A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophy
Skeletal Muscle (2020)